PRLD Stock Price
PRLD
PRLD stock price is $3.78 (-1.56% on the day), giving PRLD a market cap of $306.45M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
PRLD Stock Overview
- Price
- $3.78
- Previous close
- $3.84
- Open
- $3.87
- Market cap
- $306.45M
- 1-year price target
- $9.00
- MarketXLS Rank
- 40
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein, which along with SMARCA4 controls gene regulation through chromatin remodeling, which is in phase 1 clinical trial for the treatment of advanced or metastatic solid tumors; PRT7732, selective and orally bioavailable SMARCA2 degraders, which is in phase 1 multi-dose escalation trial for the treatment of advanced or metastatic solid tumors and; PRT2527, a Cyclin-dependent Kinase 9 inhibitor, which is in phase 1 dose-escalation and confirmation for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PRLD | $3.78 | -1.6% | 174.75K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |